Valtecne (VLT) H2 2024 earnings summary

Executive summary

• FY 2024 revenues were €30.4M, nearly flat year-over-year, as medical growth offset industrial decline.

• Medical devices now represent nearly 70% of total business, up from 60% in 2023, with record revenues in this segment.

• EBITDA rose 6.4% to €6.2M, with adjusted EBITDA up 4.1% to €7.5M, reflecting improved margins.

• Net profit increased 7.4% to €3.4M, driven by strong operating margins and financial results.

• Acquisition of 60% of Utilità S.r.l. significantly accelerated growth and profitability, reflected in pro-forma results.

Financial highlights

• Statutory 2024 revenues were €30.4M, down 1.1% year-over-year; pro-forma revenues reached €36.9M.

• Medical segment revenues grew 15.1% to €21.3M, while industrial revenues fell 25.4% to €9.1M.

• Adjusted EBITDA margin on value of production improved to 25.1% (up 230 bps).

• Free cash flow reached €4.4M despite €2.5M in investments.

• Net financial position improved to €6.8M cash positive at year-end.

Outlook and guidance

• Orthopaedic and medical device markets are expected to grow, with a 4.3% CAGR forecast for 2025–2027.

• FY 2025 anticipated to show slight top-line growth and further shift toward medical sector.

• Order backlog remains near historic highs; customer base and product portfolio are expanding.

• Industrial segment expected to remain weak; management considering divestments and new investments in medical capacity.